Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
netupitant
Description:
A neurokinin-1 receptor antagonist drug used to prevent chemotherapy-induced nausea and vomiting.
Primary topic:
Nausea and vomiting management (74%)
Related topics:
Nausea and vomiting management (74%),
Analytical Methods in Pharmaceuticals (9%)
Wikidata ID:
wiki/Q19598139
OpenAlex ID:
keywords/netupitant
A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy
2014
·
M. Aapro
, H. Rugo
, et al.
·
Annals of Oncology
·
262
PDF
Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study
2014
·
P.J. Hesketh
, G. Rossi
, et al.
·
Annals of Oncology
·
241
PDF
Antiemetics: American Society of Clinical Oncology Focused Guideline Update
2015
·
Paul J. Hesketh
, Kari Bohlke
, et al.
·
Journal of Clinical Oncology
·
217
Management of Chemotherapy-Induced Nausea and Vomiting: Focus on Newer Agents and New Uses for Older Agents
2013
·
Rudolph M. Navari
·
Drugs
·
204
A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy
2014
·
R.J. Gralla
, S.M. Bosnjak
, et al.
·
Annals of Oncology
·
200
Delayed Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Incidence, and Current Management
2017
·
Bernardo L. Rapoport
·
Frontiers in Pharmacology
·
140
PDF
2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy
2016
·
Jørn Herrstedt
, Fausto Roila
, et al.
·
Supportive Care in Cancer
·
133
A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)
2017
·
L. Zhang
, S. Lu
, et al.
·
Annals of Oncology
·
116
PDF
Crystal structures of the human neurokinin 1 receptor in complex with clinically used antagonists
2018
·
Jendrik Schöppe
, Janosch Ehrenmann
, et al.
·
Nature Communications
·
111
PDF
Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects
2012
·
Marigo Stathis
, Claudio Pietra
, et al.
·
European Journal of Pharmacology
·
87
Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis
2018
·
Takamichi Yokoe
, Tetsu Hayashida
, et al.
·
The Oncologist
·
67
In vitro and in vivo pharmacological characterization of the novel NK1 receptor selective antagonist Netupitant
2012
·
Anna Rizzi
, Barbara Campi
, et al.
·
Peptides
·
66
Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK1) receptor antagonists
2017
·
Snežana M. Bošnjak
, Richard J. Gralla
, et al.
·
Supportive Care in Cancer
·
62
PDF
Netupitant PET imaging and ADME studies in humans
2013
·
Tulla Spinelli
, Selma Calcagnile
, et al.
·
The Journal of Clinical Pharmacology
·
58
Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting
2018
·
Rudolph M. Navari
, Lee S. Schwartzberg
·
OncoTargets and Therapy
·
56
PDF
NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron
2016
·
Matti Aapro
, Meinolf Karthaus
, et al.
·
Supportive Care in Cancer
·
56
PDF
Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of midazolam, erythromycin, and dexamethasone
2013
·
Corinna Lanzarotti
, Giorgia Rossi
·
Supportive Care in Cancer
·
45
Netupitant and palonosetron trigger NK1 receptor internalization in NG108-15 cells
2014
·
Ajit G. Thomas
, Marigo Stathis
, et al.
·
Experimental Brain Research
·
43
PDF
Design and synthesis of a novel, achiral class of highly potent and selective, orally active neurokinin-1 receptor antagonists
2005
·
Torsten Hoffmann
, Michael Bös
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
41
The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting
2015
·
Rudolph M. Navari
·
Expert Opinion on Drug Safety
·
40
Efficient Synthesis of Novel NK1 Receptor Antagonists: Selective 1,4-Addition of Grignard Reagents to 6-Chloronicotinic Acid Derivatives
2006
·
Fabienne Hoffmann-Emery
, Hans Hilpert
, et al.
·
The Journal of Organic Chemistry
·
38
Differential and additive suppressive effects of 5-HT3 (palonosetron)- and NK1 (netupitant)-receptor antagonists on cisplatin-induced vomiting and ERK1/2, PKA and PKC activation
2015
·
Nissar A. Darmani
, Weixia Zhong
, et al.
·
Pharmacology Biochemistry and Behavior
·
37
Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy
2019
·
Lee Schwartzberg
, Rudolph Navari
, et al.
·
The Oncologist
·
35
PDF
Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: Rolapitant and NEPA (netupitant/palonosetron)
2015
·
Camilo Rojas
, Barbara S. Slusher
·
Cancer Treatment Reviews
·
35
Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives
2013
·
Selma Calcagnile
, Corinna Lanzarotti
, et al.
·
Supportive Care in Cancer
·
35
Show more works
View as search
Works count:
309
Citation count:
3,818
Year
Topic
Type